Based at the Royal Devon & Exeter NHS Hospital, this continuing study investigates the performance of Oricol in detecting both colorectal and other gastrointestinal diseases. The cohort includes 50 retrospective CRC samples and 250 prospective cases exploring pancreatic, lung adenocarcinoma, and urothelial cancer controls. The study supports the development of the Oricol v1 prototype (completed in April 2024), validating an improved sample buffer and multiomic analytical approach. The outcomes will drive additional scientific publications and provide the foundation for real-world NHS implementation studies (ORI-04).